(Gastric Cancer) Nivolumab Plus Chemotherapy: Is It Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- January 26, 2022
- Reading time: 2 minutes
On January 11, 2022, Yoon-Koo Kang and colleagues at the University of Ulsan College of Medicine published in the medical journal The Lancet the efficacy and safety results of the ATTRACTION-4 Phase 2/3 trial evaluating first-line treatment with the anti-PD-1 antibody nivolumab plus chemotherapy in patients with HER2-negative unresectable or recurrent gastric cancer and gastroesophageal junction (GEJ) cancer.
ATTRACTION-4 Phase 2/3 Trial Design
ATTRACTION-4 was a multicenter, double-blind trial. Patients with HER2-negative unresectable or recurrent gastric cancer and GEJ cancer (N=724) were randomized 1:1 to:
- Nivolumab group: 360 mg nivolumab + chemotherapy on Day 1 of each 3-week cycle (N=362)
- Placebo group: Placebo + chemotherapy (N=362)
The primary endpoint was progression-free survival (PFS).
Efficacy Results
At a median follow-up of 11.6 months, median PFS was:
- Nivolumab group: 10.45 months / Placebo group: 8.34 months
- The nivolumab group showed a 32% reduction in the risk of disease progression or death
At a median follow-up of 26.6 months, median overall survival (OS) was:
- Nivolumab group: 17.45 months / Placebo group: 17.15 months
- The nivolumab group showed a 10% reduction in the risk of death for OS
Safety Profile
Grade 3–4 adverse events most commonly confirmed in patients were:
- Neutropenia: Nivolumab 20% (N=71/359) / Placebo 16% (N=57/358)
- Thrombocytopenia: Nivolumab 9% (N=34) / Placebo 9% (N=33)
- Serious adverse events: Nivolumab 25% (N=88) / Placebo 14% (N=51)
- Most common: decreased appetite (Nivolumab 5% [N=18] / Placebo 3% [N=10])
Conclusions
Based on the ATTRACTION-4 results, Yoon-Koo Kang and colleagues concluded that first-line nivolumab plus chemotherapy significantly improved PFS in HER2-negative unresectable or recurrent gastric cancer and GEJ cancer patients. Although the improvement in OS was more modest, this combination is expected to become a promising new first-line treatment option.
Source: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00692-6/fulltext
- Immunotherapy
- Clinical trial drug
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4